CO6511199A2 - Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf- beta - Google Patents

Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf- beta

Info

Publication number
CO6511199A2
CO6511199A2 CO12035227A CO12035227A CO6511199A2 CO 6511199 A2 CO6511199 A2 CO 6511199A2 CO 12035227 A CO12035227 A CO 12035227A CO 12035227 A CO12035227 A CO 12035227A CO 6511199 A2 CO6511199 A2 CO 6511199A2
Authority
CO
Colombia
Prior art keywords
chemotherapeutic agent
tgf
inhibitor
combination
antisense oligonucleotide
Prior art date
Application number
CO12035227A
Other languages
English (en)
Spanish (es)
Inventor
Karl-Hermann Schilingensiepen
Frank Jaschinski
Tanja Rothammer
Anneliese Schneider
Original Assignee
Antisense Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41278403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6511199(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antisense Pharma Gmbh filed Critical Antisense Pharma Gmbh
Publication of CO6511199A2 publication Critical patent/CO6511199A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CO12035227A 2009-07-30 2012-02-29 Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf- beta CO6511199A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09166893 2009-07-30

Publications (1)

Publication Number Publication Date
CO6511199A2 true CO6511199A2 (es) 2012-08-31

Family

ID=41278403

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12035227A CO6511199A2 (es) 2009-07-30 2012-02-29 Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf- beta

Country Status (17)

Country Link
US (1) US8476246B2 (cg-RX-API-DMAC10.html)
EP (1) EP2340308B1 (cg-RX-API-DMAC10.html)
JP (1) JP2013500313A (cg-RX-API-DMAC10.html)
KR (1) KR20120107456A (cg-RX-API-DMAC10.html)
CN (1) CN102712924A (cg-RX-API-DMAC10.html)
AU (1) AU2010277554B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012002102A2 (cg-RX-API-DMAC10.html)
CA (1) CA2769618A1 (cg-RX-API-DMAC10.html)
CL (1) CL2012000247A1 (cg-RX-API-DMAC10.html)
CO (1) CO6511199A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP12011689A (cg-RX-API-DMAC10.html)
IL (1) IL217821A0 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN00969A (cg-RX-API-DMAC10.html)
MX (1) MX2012001244A (cg-RX-API-DMAC10.html)
PE (1) PE20121495A1 (cg-RX-API-DMAC10.html)
RU (1) RU2012107535A (cg-RX-API-DMAC10.html)
WO (1) WO2011012713A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062421A1 (en) 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
TWI454281B (zh) * 2011-10-06 2014-10-01 Nat Univ Tsing Hua 硼酸於硼中子捕獲治療肝癌之用途
WO2013124869A2 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations
CA2903239A1 (en) * 2013-03-14 2014-10-02 Oncogenex Technologies Inc. Custirsen treatment with reduced toxicity
ES2753580T3 (es) * 2014-05-23 2020-04-13 Inst Nat Sante Rech Med Procedimientos para determinar si un paciente logrará una respuesta después de la radioterapia
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
US11759530B2 (en) * 2014-11-17 2023-09-19 City Of Hope TKI permeability enhancers
CN108139375A (zh) 2015-06-26 2018-06-08 贝斯以色列女执事医疗中心股份有限公司 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
KR101843985B1 (ko) 2016-02-09 2018-03-30 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2018081817A2 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
US20220145304A1 (en) * 2019-03-14 2022-05-12 The Research Foundation For The State University Of New York Modified micrornas and their use in the treatment of cancer
GB201908012D0 (en) * 2019-06-05 2019-07-17 Io Biotech Aps TGF-Beta vaccine
CN112933238A (zh) * 2021-02-02 2021-06-11 石河子大学 抑制TGF-βR1基因表达的物质与顺铂在治疗和/或预防食管癌中的应用
CN113425855B (zh) * 2021-06-28 2023-11-07 深圳瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用
WO2025193774A1 (en) * 2024-03-12 2025-09-18 The Regents Of The University Of California Methods of identifying and treating an immune poor cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
EP0092574B1 (en) 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
EP0856579A1 (en) * 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US7807844B2 (en) * 2003-09-04 2010-10-05 Nihon University TGF-β gene expression inhibitor
ZA200602941B (en) * 2003-11-13 2007-07-25 Genentech Inc Screening assays and methods of tumor treatment
AU2004292180A1 (en) * 2003-11-13 2005-06-02 Genentech, Inc. Screening assays and methods of tumor treatment
WO2005059133A2 (en) 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent
US20070155685A1 (en) * 2004-02-27 2007-07-05 Karl-Hermann Schlingensiepen Pharmaceutical composition
EP1992360A4 (en) * 2006-02-01 2010-02-17 Univ Tokyo COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT
JP5322476B2 (ja) * 2008-03-31 2013-10-23 テルモ株式会社 リポソームの製造装置およびリポソームの製造方法

Also Published As

Publication number Publication date
BR112012002102A2 (pt) 2017-05-02
IN2012DN00969A (cg-RX-API-DMAC10.html) 2015-04-10
AU2010277554B2 (en) 2015-02-19
PE20121495A1 (es) 2012-11-19
CN102712924A (zh) 2012-10-03
US20120027873A1 (en) 2012-02-02
IL217821A0 (en) 2012-03-29
WO2011012713A1 (en) 2011-02-03
EP2340308B1 (en) 2014-12-24
AU2010277554A1 (en) 2012-03-01
CL2012000247A1 (es) 2013-07-05
KR20120107456A (ko) 2012-10-02
EP2340308A1 (en) 2011-07-06
JP2013500313A (ja) 2013-01-07
MX2012001244A (es) 2012-03-26
CA2769618A1 (en) 2011-02-03
US8476246B2 (en) 2013-07-02
RU2012107535A (ru) 2013-09-10
ECSP12011689A (es) 2012-06-29

Similar Documents

Publication Publication Date Title
ECSP12011689A (es) Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf-beta
UA105390C2 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
CR10748A (es) Compuesto de indol
CL2013000423A1 (es) Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno.
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
BRPI0814874A2 (pt) combinação de agente antimitótico e inibidor da aurora quinase como tratamento anticâncer.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
CL2015002145A1 (es) Preparación, usos y formas sólidas de ácido obeticólico (divisional de solicitud n° 3475-2014)
CL2008000188A1 (es) Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
CL2017002682A1 (es) Forma de dosificación resistente a alteraciones con liberación inmediata y resistencia contra la extracción por solventes
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
MX2017004318A (es) Composiciones y metodos para el tratamiento y profilaxis de infecciones del sitio quirurgico.
TR201010683A1 (tr) Vildagliptin formülasyonları.
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
AR084487A1 (es) Componente prostesico con una superficie deslizante que contiene un recubrimiento antimicrobiano
CL2009002167A1 (es) Formulacion farmaceutica para administracion endovenosa que comprende un compuesto derivado de conjugados de camptotecina-polimero biocompatibles y biodegradables, un agente de estabilizacion, uno o varios tampones y un tensoactivo, util para el tratamiento del cancer.
ECSP11010856A (es) Composición farmacéutica sólida
CL2008000092A1 (es) Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria.